Read More Pharma Industry News Zydus Lifesciences (NSE: ZYDUSLIFE) wins NMPA approval for Desidustat in China, unlocking access to 120 million CKD patients Zydus Lifesciences' novel oral drug Desidustat receives China NMPA approval for CKD anaemia, unlocking a market of 120 million patients. Read the strategic analysis. byVenkateshMarch 16, 2026